Methods of treating pterygium

a technology of pterygium and keloid, applied in the field of eye and skin conditions, can solve the problems of high recurrence rate of surgical management of pterygium and negatively affect the quality of life of patients
US20140186336A1Active Publication Date: 2014-07-03PHAM RANDAL TANH HOANG
0 Cites 27 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
PHAM RANDAL TANH HOANG
Publication Date
2014-07-03

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and / or a non-steroidal anti-inflammatory drug (NSAID) to a subject.
Need to check novelty before this filing date? Find Prior Art

Description

RELATED APPLICATIONS

[0001] The present application claims the benefit of U.S. Provisional Patent Application Ser. No. 61 / 746,778, filed Dec. 28, 2012, which is herein incorporated by reference in its entirety.TECHNICAL FIELD

[0002] The present disclosure relates to methods of treating eye and skin conditions, in particular, methods for treating pterygium and keloid, including treating recurrence of these conditions following surgery.BACKGROUND

[0003] Pterygium is a fibrovascular conjunctiva proliferation of the supra-ocular surface with extension to the cornea. Surgery is the accepted method for primary treatment of pterygium; however, one of the major limitations of surgical management of pterygium is the high recurrence rate. The growth factor, vascular endothelial growth factor (VEGF), has been shown to be highly expressed in pterygium and in the growing blood vessels that are associated with pterygium recurrence.

[0004] Bevacizumab (Avastin®) is a 149-Kd full length humanized anti-vasc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More